By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Meiji Seika Kaisha, Ltd. 

4-16-1, Hatchobori

Chuo-Ku  Tokyo  104-8002  Japan
Phone: 81-3-3272-6511 Fax: 81-3-3271-3528



Company News
Celentyx Enters Into Agreement With Meiji Seika Kaisha, Ltd. To Discover New Development Paths For Meiji Drug Candidates Using Celentyx's Novel Clinical Indication Profiling(TM) 8/24/2009 11:54:55 AM
Amalyte and Meiji Seika Kaisha, Ltd. Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds 6/8/2009 9:48:28 AM
ACADIA Pharmaceuticals, Inc. (ACAD) And Meiji Seika Kaisha, Ltd. Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs 3/25/2009 10:18:42 AM
Symphogen A/S and Meiji Seika Kaisha, Ltd. Achieve Milestone in Discovery Collaboration for Recombinant Polyclonal Antibody, Sym006 12/4/2008 10:21:24 AM
Symphogen A/S And Meiji Seika Kaisha, Ltd. Enter Agreement For Recombinant Polyclonal Antibody Product 12/11/2006 12:50:10 PM
Cerexa, Inc. Expands Portfolio Of Novel Anti-Infective Therapies Through In-Licensing Agreement With Meiji Seika Kaisha, Ltd. 11/1/2006 12:24:23 PM
MediciNova, Inc. Announces The Acquisition Of Two Novel Antithrombotic Agents From Meiji Seika Kaisha, Ltd. 11/1/2006 11:18:37 AM
Meiji Seika Kaisha, Ltd. And Solvay Seiyaku Obtain Additional Approval For Fluvoxamine Maleate10/19/2005 5:13:22 PM
Nippon Organon KK Licenses Antidepressant To Meiji Seika Kaisha, Ltd.10/19/2005 5:11:19 PM
Meiji Seika Kaisha, Ltd. Subsidiary Receives Sales Approval For "MEIACT" In Spain10/19/2005 5:11:05 PM